NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
17.04
-0.21 (-1.22%)
At close: May 29, 2026, 4:00 PM EDT
17.18
+0.14 (0.82%)
After-hours: May 29, 2026, 7:50 PM EDT
NovoCure Revenue
NovoCure had revenue of $174.06M in the quarter ending March 31, 2026, with 12.30% growth. This brings the company's revenue in the last twelve months to $674.41M, up 8.48% year-over-year. In the year 2025, NovoCure had annual revenue of $655.35M with 8.28% growth.
Revenue (ttm)
$674.41M
Revenue Growth
+8.48%
P/S Ratio
2.93
Revenue / Employee
$420,196
Employees
1,605
Market Cap
1.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 655.35M | 50.13M | 8.28% |
| Dec 31, 2024 | 605.22M | 95.88M | 18.82% |
| Dec 31, 2023 | 509.34M | -28.50M | -5.30% |
| Dec 31, 2022 | 537.84M | 2.81M | 0.53% |
| Dec 31, 2021 | 535.03M | 40.67M | 8.23% |
| Dec 31, 2020 | 494.37M | 143.05M | 40.72% |
| Dec 31, 2019 | 351.32M | 103.25M | 41.62% |
| Dec 31, 2018 | 248.07M | 71.04M | 40.13% |
| Dec 31, 2017 | 177.03M | 94.14M | 113.57% |
| Dec 31, 2016 | 82.89M | 49.80M | 150.52% |
| Dec 31, 2015 | 33.09M | 17.60M | 113.60% |
| Dec 31, 2014 | 15.49M | 5.13M | 49.53% |
| Dec 31, 2013 | 10.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AdaptHealth | 3.29B |
| Enovis | 2.28B |
| Integer Holdings | 1.86B |
| Haemonetics | 1.33B |
| Neogen | 870.56M |
| TransMedics Group | 635.89M |
| UFP Technologies | 608.85M |
| PROCEPT BioRobotics | 322.02M |
NVCR News
- 8 days ago - NovoCure Proxy statement: Proxy filing - Filings
- 25 days ago - Novocure price target raised to $17 from $13.50 at Wells Fargo - TheFly
- 4 weeks ago - Novocure price target raised to $20 from $16 at Evercore ISI - TheFly
- 4 weeks ago - Novocure reports Q1 EPS (62c), consensus (51c) - TheFly
- 4 weeks ago - Novocure raises FY26 revenue view to $690M-$710M from $675M-$705M - TheFly
- 4 weeks ago - NovoCure Earnings Call Transcript: Q1 2026 - Transcripts
- 4 weeks ago - NovoCure Quarterly report: Q1 2026 - Filings
- 4 weeks ago - NovoCure Earnings release: Q1 2026 - Filings